Latest News

The FDA has provided an update on efforts to increase supply of estradiol transdermal patches as demand increases.

NeoBLAST, a phase 2/3 Canadian trial, tests whether active surveillance can safely replace surgery/radiation in MIBC patients with complete response to neoadjuvant therapy.

This episode explores evolving approaches to sexual wellness, innovation in premature ejaculation, the need for patient education, and integrating sexual health products into clinical care across the lifespan.

Martin Schoen, MD, PhD, discusses how study methodology, patient selection, and confounding can shape real-world evidence findings in prostate cancer.

In this Q&A, Shiv B. Patel, MD, reflects on how prostate cancer screening has evolved from a one-size-fits-all approach to a more individualized strategy.

The target enrollment goal has been reached in the phase 3 BiPASS study, evaluating PSMA-PET plus MRI for prostate cancer detection.

Routine cardiovascular specialist referral improved cholesterol control in patients with prostate cancer but did not reduce cardiovascular events.

LUGPA CEO Celeste Kirschner, CAE, MHSA, outlines the association's top 2027 priorities: fee schedule reform, site-neutral payments, prior authorization, and practice consolidation.

Martin Schoen, MD, PhD, discusses factors guiding ARPI selection in prostate cancer and how real-world evidence can help inform treatment decisions.

A recap of the FDA submissions and regulatory decisions in urology from August 2026.

Prof Declan Murphy discusses PROTEUS pathologic responses with apalutamide plus ADT and their implications for future treatment strategies.

In this Q&A, Zachary Feuer, MD, discusses the implementation of a telehealth-based rapid access program for evaluating men with an elevated PSA.

Timothy D. McClure, MD, discusses 2-year PRESERVE trial safety data and 12-month AUA findings linking prostate size to IPSS improvement after focal IRE.